dopaminergic neuron replacement

Class

autologous iPSC-derived cell therapy

Dopaminergic neuron replacement targets the loss of dopamine-producing neurons in the substantia nigra, a midbrain structure whose projections to the striatum (the nigrostriatal pathway) normally coordinate movement. In Parkinson's disease, progressive degeneration of these neurons reduces striatal dopamine, producing tremor, rigidity, and slowed movement. Conventional pharmacologic therapy supplies dopamine or its precursors systemically, but this approach is symptomatic and becomes less reliable as disease progresses, often accompanied by fluctuating drug levels and motor complications. Cell replacement therapy takes a different approach: rather than adding dopamine chemically, it aims to reconstitute the missing cell population itself. Autologous induced pluripotent stem cell (iPSC)-derived therapies reprogram a patient's own cells into a stem-cell-like state, then differentiate them into dopaminergic neuron precursors that are surgically implanted into the brain, with the intent that they mature, integrate into local circuitry, and provide a sustained, endogenously regulated source of dopamine. Because the cells originate from the patient, this strategy is intended to reduce the risk of immune rejection compared with donor-derived tissue. This mechanism is relevant chiefly to Parkinson's disease and other conditions marked by selective neuronal loss where restoring cellular function, not just neurotransmitter levels, is the underlying therapeutic goal.